List of Excipients in Branded Drug COREG CR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Woodward Pharma Services LLC	COREG CR	carvedilol phosphate	69784-383	CELLULOSE, MICROCRYSTALLINE
Woodward Pharma Services LLC	COREG CR	carvedilol phosphate	69784-383	CROSPOVIDONE
Woodward Pharma Services LLC	COREG CR	carvedilol phosphate	69784-383	HYDROGENATED CASTOR OIL

Coreg CR Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

Coreg CR is an extended-release capsule containing carvedilol phosphate, a nonselective beta-adrenergic and alpha-1 adrenergic blocker. Its commercial differentiation depends on multiparticulate release control rather than on the active ingredient alone. The principal opportunities are generic substitution, lower-cost controlled-release manufacturing, excipient and coating optimization, patient-friendly capsule formats, and lifecycle products that improve administration or adherence.

The strongest formulation strategy is a multiparticulate system combining immediate-release and extended-release populations. That architecture can reproduce carvedilol exposure while reducing the risk that a single matrix failure causes dose dumping. Commercial success depends on matching the reference product's dissolution profile, pharmacokinetics, food effect, capsule performance, and stability.

What is Coreg CR and how is it formulated?

Coreg CR is the extended-release version of carvedilol marketed by GlaxoSmithKline. The product was approved by the U.S. Food and Drug Administration in 2006 for hypertension and heart failure-related indications associated with carvedilol therapy. The available strengths are 10 mg, 20 mg, 40 mg, and 80 mg carvedilol phosphate extended-release capsules.[1]

Coreg CR uses a multiparticulate delivery design. The capsule contains coated particles or beads that release carvedilol over an extended period. The dosage form is intended for once-daily administration, while immediate-release carvedilol tablets are generally administered twice daily in the labeled indications.[1]

Coreg CR dosage-form architecture

Attribute	Coreg CR
Active ingredient	Carvedilol phosphate
Dosage form	Extended-release capsule
Strengths	10 mg, 20 mg, 40 mg, 80 mg
Release technology	Multiparticulate extended-release system
Administration	Once daily, generally with food
Key therapeutic areas	Heart failure and hypertension
Reference sponsor	GlaxoSmithKline
FDA application	NDA 022012
Primary commercial constraint	Reproducing release and food-effect behavior
Main formulation opportunity	Lower-cost equivalent multiparticulate capsule

The label instructs patients to take Coreg CR with food. This is commercially important because food can alter carvedilol absorption, and the approved product design incorporates a controlled administration condition rather than treating food exposure as a minor variable.[1]

What excipients are used in Coreg CR?

The Coreg CR label identifies inactive ingredients associated with the capsule and coated-particle system. The formulation uses conventional pharmaceutical excipients for pellet formation, film coating, release control, glidancy, capsule manufacture, and color adjustment.[1]

Publicly disclosed excipient categories include:

• Sugar spheres or sucrose-based starter cores
• Povidone as a binder
• Ethylcellulose as a release-controlling polymer
• Hypromellose as a film-forming or protective polymer
• Talc as an anti-tacking and processing aid
• Triethyl citrate as a plasticizer
• Gelatin for the capsule shell
• Titanium dioxide and approved colorants for capsule appearance

The exact commercial formulation should be confirmed against the current FDA-approved labeling and product-quality records before development or litigation use. Excipient identity alone does not establish equivalence. Particle size, drug loading, coating weight gain, polymer grade, plasticizer ratio, curing conditions, and dissolution specifications are often more important than the ingredient list.

Functional role of the excipient system

Excipient class	Likely function	Commercial relevance
Sugar spheres	Inert pellet core	Supports uniform layering and scalable bead manufacture
Povidone	Binder	Controls drug-layer adhesion and mechanical integrity
Ethylcellulose	Water-insoluble release membrane	Primary control over carvedilol diffusion
Hypromellose	Film former and protective layer	Improves coating continuity and process robustness
Triethyl citrate	Plasticizer	Reduces film brittleness and supports consistent release
Talc	Anti-tacking aid	Improves coating yield and reduces agglomeration
Gelatin	Capsule shell	Enables capsule filling and product identification
Titanium dioxide and colorants	Appearance and identification	Supports brand differentiation and regulatory consistency

How does the Coreg CR release mechanism create excipient opportunities?

The key commercial opportunity is to control carvedilol release without duplicating every excipient used by the reference product. A generic applicant can use a different formulation if it demonstrates pharmaceutical equivalence and bioequivalence under the applicable FDA pathway.

Ethylcellulose-coated pellets are attractive because they can provide extended release through diffusion. Release can be adjusted through:

1. Polymer weight gain.
2. Ethylcellulose viscosity grade.
3. Pore-former concentration.
4. Plasticizer level.
5. Coating curing conditions.
6. Pellet diameter and surface area.
7. Drug-layer thickness.
8. Capsule fill composition.

A multiparticulate system can also distribute the dose across several release populations. For example, a formulation may contain immediate-release pellets plus two or more extended-release pellet fractions with different coating levels. That approach gives the developer more control over the initial exposure and terminal release phase.

Immediate-release and extended-release fractions

A commercially practical Coreg CR substitute may use:

• An immediate-release fraction to establish early carvedilol exposure.
• A lightly coated fraction for intermediate release.
• A heavily coated fraction for later release.
• A capsule shell compatible with moisture and mechanical requirements.

The objective is not simply to produce a 24-hour dissolution curve. The product must maintain an exposure profile that is comparable to the reference product under fed and fasting conditions, subject to the FDA's applicable bioequivalence standards.[2]

What excipient strategies can reduce Coreg CR manufacturing cost?

The highest-value cost reductions are likely to come from process simplification and coating efficiency rather than from replacing low-cost excipients individually.

1. Replace sugar spheres with directly formed pellets

Extrusion-spheronization or fluid-bed pelletization can reduce dependence on proprietary starter cores. The approach may support higher drug loading and lower capsule fill weight. It also creates risks involving pellet density, friability, size distribution, and coating uniformity.

2. Use aqueous coating instead of solvent-intensive processing

Aqueous ethylcellulose dispersions can reduce solvent-handling requirements. The developer must control coalescence, residual moisture, tackiness, and curing. Aqueous processing can also affect release stability during storage.

3. Increase drug loading

Higher drug loading can reduce the number of pellets and the capsule volume required for each strength. The tradeoff is a narrower process window for content uniformity and release control. Carvedilol is a potent active ingredient, so the commercial benefit may be meaningful, but the optimal loading depends on the target product profile.

4. Standardize one coating platform across strengths

A common bead platform across 10 mg, 20 mg, 40 mg, and 80 mg strengths can lower equipment changeover and analytical costs. Strength scaling through fill weight is simpler than creating separate release systems for each dosage strength.

5. Use functional excipients with established regulatory precedent

Ethylcellulose, hypromellose, povidone, triethyl citrate, and talc have extensive pharmaceutical use. Familiar excipients can reduce regulatory friction compared with novel polymers, although the manufacturing process still requires product-specific validation.

6. Improve capsule moisture protection

Carvedilol phosphate extended-release pellets can be sensitive to moisture-driven changes in coating permeability. High-barrier blister packaging, desiccant bottles, or improved capsule-shell specifications may protect dissolution performance. Packaging can be a lower-risk commercial lever than changing the release polymer.

What patents protect Coreg CR and when does Coreg CR lose exclusivity?

Coreg CR's exclusivity has historically depended on three separate layers:

1. FDA regulatory exclusivity.
2. Orange Book-listed patents.
3. Manufacturing know-how and formulation process controls.

The FDA's Orange Book is the controlling public source for current listed patents, pediatric exclusivity, and the status of approved generic applications.[3] Patent expiration dates should be assessed from the current Orange Book entry and the underlying patent records because terminal disclaimers, patent-term adjustment, pediatric extensions, reexamination, and litigation settlements can change the effective timing.

Coreg CR is no longer protected by the original period of new-drug exclusivity. Commercial entry is therefore principally a patent, regulatory, and bioequivalence issue rather than an active NCE exclusivity issue.

Patent categories relevant to Coreg CR

Patent category	Commercial function	Risk to a generic applicant
Extended-release formulation patents	Protect pellet, coating, or release architecture	May require Paragraph IV certification or design-around
Method-of-use patents	Protect use in heart failure, hypertension, or dosing regimens	May limit labeling or require a skinny-label strategy
Manufacturing patents	Protect coating, layering, curing, or pellet production	Can raise process infringement risk
Packaging or stability patents	Protect moisture control or shelf-life systems	Usually lower risk if alternative packaging is used
Drug-substance patents	Protect carvedilol phosphate or related solid forms	Generally less central than formulation patents for an established product

A development team should separate formulation patent risk from freedom to operate. A formulation may achieve bioequivalence while still practicing a patent claim directed to coating composition, bead structure, or release kinetics.

Which companies are challenging Coreg CR, and what is the Paragraph IV risk?

Generic applicants can challenge listed Coreg CR patents through an ANDA containing a Paragraph IV certification. The certification alleges that a listed patent is invalid, unenforceable, or will not be infringed by the proposed product. The first substantially complete Paragraph IV filing can create a 180-day generic exclusivity period under applicable FDA rules, subject to forfeiture and other statutory conditions.[4]

The relevant competitive questions are:

• Which applicants filed ANDAs referencing Coreg CR?
• Which applicants certified Paragraph IV?
• Whether the reference sponsor filed patent litigation within 45 days.
• Whether litigation triggered a 30-month stay.
• Whether the parties settled.
• Whether the applicant's proposed label omits patented methods of use.
• Whether the applicant is eligible for first-filer exclusivity.

Public commercial databases and FDA records should be reconciled because ANDA applicants may be confidential before approval, and patent litigation records may not identify every development program. The Orange Book identifies listed patents but does not provide a complete market-share or launch forecast.

What is the FDA regulatory status of Coreg CR?

Coreg CR was approved under an NDA as a prescription extended-release product. A generic competitor would normally pursue an ANDA demonstrating pharmaceutical equivalence and bioequivalence to the reference listed drug, rather than repeating the full clinical efficacy program.[2]

For a multiparticulate extended-release product, the regulatory burden is concentrated in:

• Active ingredient equivalence.
• Dosage-form equivalence.
• Strength equivalence.
• Inactive-ingredient safety.
• In vitro dissolution.
• Fed and fasting bioequivalence.
• Alcohol-induced dose-dumping assessment where applicable.
• Stability and container-closure performance.
• Capsule content uniformity.
• Multiparticulate size and coating controls.

FDA's product-specific guidance should control the design of comparative dissolution and pharmacokinetic studies. The guidance may specify fed and fasting studies, sampling duration, strength selection, and dissolution media.[5]

What formulation patents and method-of-use patents matter commercially?

Formulation patents are usually more important for Coreg CR than broad carvedilol composition patents because carvedilol itself is an established molecule. The highest-risk claims are those that cover:

• A capsule containing multiple pellet populations.
• Carvedilol layered onto inert cores.
• Ethylcellulose or related polymer membranes.
• Defined release percentages at specified time points.
• Specific combinations of immediate-release and sustained-release particles.
• A once-daily carvedilol regimen using a controlled-release capsule.

Method-of-use claims can affect labeling strategy. If a patent covers a particular indication or dosing method, an ANDA applicant may consider a label that omits the patented use, provided the remaining label does not encourage infringement. That strategy must be evaluated against the actual claim language and the product's proposed labeling.

How strong is the Coreg CR patent estate?

The estate is strongest where patent claims combine structural and functional limitations. A claim directed only to a broad extended-release carvedilol concept may face validity and prior-art challenges. A claim that specifies pellet construction, polymer composition, coating level, release profile, and pharmacokinetic performance can be harder to design around but may be narrower.

Patent strength should be scored across four dimensions:

Dimension	Strong position	Weak position
Claim scope	Covers multiple pellet and coating implementations	Depends on narrow excipient ratios
Validity	Supported by unexpected release or food-effect data	Reads on common multiparticulate practice
Infringement	Product architecture is readily observable	Requires inference from process conditions
Design-around cost	Alternative system requires new clinical or BE work	Alternative polymers or pellet methods are available

The commercial barrier may therefore persist after nominal patent expiry through know-how, scale-up difficulty, and bioequivalence failure. Those barriers are weaker than enforceable patent rights but can delay entry.

What commercial opportunities exist for Coreg CR excipients?

Generic Coreg CR capsules

The largest opportunity is a lower-priced carvedilol phosphate extended-release capsule. The addressable market includes patients who prefer once-daily dosing, prescribers seeking simplified regimens, and payers seeking substitution for the branded product.

Authorized generic or contract manufacturing

A branded or specialty-pharma company could use an authorized generic model, regional license, or contract manufacturing agreement. The most valuable partner would have multiparticulate coating capacity, validated high-shear or fluid-bed equipment, and experience with modified-release ANDAs.

Excipient supplier partnerships

Excipient suppliers can sell:

• Functional ethylcellulose dispersions.
• Coating systems optimized for aqueous processing.
• Directly compressible or pelletizable cores.
• Plasticizer systems.
• Capsule shells with higher moisture barriers.
• Ready-to-use modified-release coating platforms.

The opportunity is stronger when the supplier can provide process development, not only raw materials. Drug developers generally value reproducible dissolution and scale-up support more than a marginal reduction in excipient unit cost.

Reformulated carvedilol products

Potential lifecycle products include:

• Sprinkle capsules containing coated pellets.
• Smaller capsules with higher drug loading.
• Lower-volume formulations for swallowing difficulty.
• Alternative capsule shells for dietary or religious requirements.
• Fixed-dose combinations with another cardiovascular agent.
• Packaging optimized for adherence and moisture protection.

Each product would face a different regulatory pathway. A meaningful change in release mechanism, strength, or patient population may require clinical or pharmacokinetic development beyond a conventional ANDA.

How does Coreg CR compare with immediate-release carvedilol?

Attribute	Coreg CR	Immediate-release carvedilol
Active ingredient	Carvedilol phosphate	Carvedilol
Typical dosing pattern	Once daily	Usually twice daily
Release mechanism	Multiparticulate extended release	Immediate release
Excipient complexity	High	Lower
Manufacturing cost	Higher due to coating and pellet controls	Generally lower
Bioequivalence challenge	Fed and fasting modified-release testing	Conventional immediate-release testing
Commercial differentiation	Convenience and regimen simplification	Lower cost and broad generic availability
Main technical risk	Dissolution and food-effect matching	Content uniformity and conventional dissolution

Coreg CR has a higher formulation barrier than immediate-release carvedilol because performance depends on coating structure and release kinetics. That barrier creates room for differentiated suppliers but also raises development cost.

What generic launch scenarios exist for Coreg CR?

The principal launch scenarios are:

1. A first-to-file Paragraph IV applicant launches after patent litigation, settlement, or favorable judgment.
2. A later generic entrant launches after all relevant listed patents expire.
3. A generic enters with a label that omits patented indications.
4. A manufacturer markets an authorized generic under a commercial agreement.
5. A technically equivalent product is delayed because it fails fed or fasting bioequivalence.
6. A manufacturer launches outside the United States in jurisdictions where patent and regulatory timing differ.

Geographic coverage matters. U.S. Orange Book status does not determine European, Canadian, Japanese, or emerging-market freedom to operate. Patent families, national validation, supplementary protection certificates, data exclusivity, and local regulatory requirements must be reviewed separately.

What manufacturing and intellectual-property barriers remain after patent expiry?

The largest technical barriers are coating uniformity, scale-up, dissolution drift, and moisture sensitivity. A small change in ethylcellulose dispersion viscosity or coating weight can alter the release curve. Pellet agglomeration can create content-uniformity failures. Curing conditions can shift release during stability testing.

Manufacturing know-how may include:

• Drug-layering sequence.
• Inlet and product temperature limits.
• Spray rate and atomization settings.
• Coating suspension solids content.
• Pellet size distribution.
• Curing time and temperature.
• Capsule fill-weight control.
• Moisture-barrier packaging.

These parameters may not appear in the public label, but they can determine whether a commercial batch matches the reference profile.

Key Takeaways

• Coreg CR is a carvedilol phosphate multiparticulate extended-release capsule in 10 mg, 20 mg, 40 mg, and 80 mg strengths.
• Its principal excipient strategy uses inert cores, binders, film-forming polymers, ethylcellulose release membranes, plasticizers, and anti-tacking agents.
• The most credible generic strategy is a controlled multiparticulate capsule with immediate-release and extended-release fractions.
• Coating weight, polymer grade, curing, pellet size, and moisture control are more commercially important than simple excipient substitution.
• Coreg CR's remaining competitive barriers are formulation patents, Paragraph IV litigation, bioequivalence, process know-how, and manufacturing scale-up.
• The leading commercial opportunities are generic entry, authorized-generic supply, functional excipient platforms, high-drug-loading pellets, sprinkle formats, and adherence-oriented lifecycle products.
• U.S. patent and exclusivity conclusions should be based on the current Orange Book and underlying patent records.

FAQs

Can Coreg CR be reformulated with a different release-control polymer?

Yes, if the alternative formulation meets applicable equivalence, safety, dissolution, stability, and bioequivalence requirements. A different polymer does not eliminate potential infringement if the resulting product practices valid formulation claims.

Is carvedilol phosphate the main patent barrier for Coreg CR?

Usually not. For an established carvedilol product, the main commercial risks are more likely to involve extended-release formulation, manufacturing, method-of-use, and release-profile claims.

Can a Coreg CR generic use a smaller capsule?

Yes, if the product maintains dose uniformity, dissolution performance, stability, manufacturability, and bioequivalence. Higher drug loading or denser pellets may reduce capsule volume but can narrow process controls.

Are ethylcellulose and hypromellose interchangeable in Coreg CR development?

No. They have different permeability, film-forming, viscosity, and processing properties. Substitution requires new formulation development and comparative release testing.

Does a successful immediate-release carvedilol product provide a direct path to Coreg CR?

No. Immediate-release carvedilol and Coreg CR have different release mechanisms, dosing schedules, food-effect considerations, and bioequivalence requirements. An extended-release product requires a separate development and regulatory strategy.

References

1. U.S. Food and Drug Administration. (2006). Coreg CR (carvedilol phosphate) extended-release capsules prescribing information. GlaxoSmithKline.

2. U.S. Food and Drug Administration. (2014). Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA: Guidance for industry. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. FDA.

4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application regulations and 180-day generic drug exclusivity. FDA.

5. U.S. Food and Drug Administration. (2024). Product-specific guidances for generic drug development. FDA.